Lepodisiran
Lilly’s Lepodisiran Shows Durable Lipoprotein(a) Reduction in Phase 2 Trial
lepodisiran, lipoprotein(a), Lp(a), cardiovascular disease, RNA interference, long-acting therapy
Actionable Insights Powered by AI
lepodisiran, lipoprotein(a), Lp(a), cardiovascular disease, RNA interference, long-acting therapy